Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegsitacianine
- Development stage
- Phase 2
- Lead developer
- OncoNano Medicine, Inc.
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegsitacianine is an intraoperative, intravenous pH-activated fluorescent imaging agent developed for real-time surgical imaging of solid tumors. It is a micellar nanoparticle composed of a hydrophilic polyethylene glycol exterior and a hydrophobic polymethyl methacrylate core covalently linked to the near-infrared (NIR) fluorophore indocyanine green 2. At physiological pH, the fluorophore remains quenched in an "off" state; upon exposure to the acidic tumor microenvironment, the nanoparticle dissociates and releases the fluorophore into an "on" state, enabling visualization with NIR light during surgery. Pegsitacianine is designed as a tumor-agnostic imaging agent compatible with most clinical cameras used for ICG imaging and aims to improve detection of cancerous tissue during cytoreductive surgery across various solid tumors[1][3][5][7].
- Brand names
- ONM-100ONM100ONM 100
- Other names
- pegsitacianineONM-100 DSONM100 DSONM 100 DS
Beyond the preview
Go deeper on pegsitacianine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegsitacianine.